Download PDF

IOTA Risk Assessment Models

Ovarian tumor analysis with Voluson™

SIMPLE RULES RISK CALCULATOR

Pre-operative classification system for ovarian tumors

The Simple Rules consist of five features typical for benign tumors (B-features) and five features typical for malignant tumors (M-features). Tumors are classified as Benign, Malignant or Inconclusive:

  • Benign: Only B-features apply
  • Malignant: Only M-features apply
  • Inconclusive: No features apply,
  • or both B- and M-features apply
Risk Calculator

Timmerman D, Van Calster B, et al. Am J Obstet Gynecol 2016;214:424-437.

LR2 RISK MODEL

Estimates probability of malignancy

LR2 uses six predictors (one clinical, plus five ultrasound):

  • Age
  • Maximal diameter of the largest solid component
  • Irregular internal cyst walls
  • Presence of papillary projections with detectable flow acoustic shadows
  • Ascites

The algorithm produces a % of probability.

Risk Model

Timmerman D, et al. J Clin Oncol 2005;23:8794-801.

ADNEX RISK MODEL

Estimates probability a tumor is benign, borderline, stage 1 cancer, stage II-IV cancer or secondary metastatic cancer

The ADNEX model uses nine predictors (three clinical, six ultrasound):

  • Age
  • Serum CA-125 level
  • Type of center
  • Maximal diameter of lesion
  • Proportion of solid tissue
  • 10 cyst locules
  • # of papillary projections
  • Acoustic shadows
  • Ascites

The algorithm produces a % for various tumor types.

ADNEX RISK MODEL ADNEX RISK MODEL
Stages
Table of Lesions
Ultrasound Obstet Gynecol 2000;16:500-505..

2019 General Electric Company – All rights reserved.
GE Healthcare reserves the right to make changes in specifications and features shown herein, or discontinue the product described at any time without notice or obligation. Contact your GE Healthcare representative for the most current information. GE, the GE Monogram, and Voluson are trademarks of General Electric Company. GE Healthcare, a division of General Electric Company. GE Medical Systems, Inc., doing business as GE Healthcare.
August 2019
JB69323XX